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Letters
RESEARCH LETTER
White Scale Sign for Xeroderma
Xeroderma, also known as xerosis cutis, is a common condi-
tion that has becomeevermore important to diagnose in light
of the number of aging patients. The condition is frequently
seen among the elderly, but it has also been observed in
youngerpatientsaffectedbyatopicdermatitis.1Theclinical fea-
tures of xeroderma are flaky, dry, and cracked skin areas. Po-
tentially because of its high frequency, xeroderma lacks diag-
nostic criteria and signs. Most clinicians tend towait tomake
the diagnosis of xeroderma until they see several skin areas
are flaky, dry, and cracked, and this tendency to delay the di-
agnosis until the condition is full-blown isunnecessary. Clear-
cut, microscopic, early signs are therefore required. We pro-
pose a dermoscopic sign that, in our experience, invariably
appears in pathologically dry skin areas.
Thebrunt of thepathologic changes inxeroderma is in the
stratumcorneumandepidermis. Singlecorneocytes shed from
the surface during thephysiologic process of renewal are nor-
mally invisible. In xeroderma, however, because the normal
process of shedding and removal of intercellular adhesion is
disturbed,2 whitish scales form. This effect of scale produc-
tion starts microscopically, usually on the shins, and later
spreads to the thighs,proximalextremities, andtrunk.Theseb-
orrheic areas of the body are always spared. When the inten-
sity is reachedthat is clinicallyobvious,branlikescalesareshed
in large amounts that can formdusty cloudswhenpatients re-
move their stockings. This clinically obvious scaling, to-
gether with pruritus, is what finally prompts most clinicians
to recognize xeroderma. Subsequently, cracks and fissures of
the stratum corneum can develop, along with asteatotic ec-
zema that causes dull, chronic inflammation.Histologic stud-
ies reveal little alterationof stratumcorneum,nor epidermis,3
early on. In later stages, eczematous changes (eczema
craquelé) develop.
Methods | Overall, we included 11 patients (6 women aged 26
to 82 years and 5men aged 67 to 87 years) in the study,which
we conducted between March 1, 2015, and April 1, 2016. The
studywasapprovedbyKantonaleEthikkommissionZürichand
written patient informed consent was obtained.
Results | Inxeroticareasofanysize, stage, andrace,white scales
were always detectable in dermoscopy (Figure, A-D). We call
this occurrence the white scale sign (WSS). These scales were
largeamountsofcorneocytes that stuck togetherandwereonly
visible by dermoscopy on dry skin (Figure, E). Onmoist skin,
however, such as when ethanol was applied for dermoscopy
(Figure,F), thewhitescalesdisappearedatonce.Whendryskin
was treatedwith emollients at the locus of a positiveWSS, the
white scalesdisappeared 15minutes later (Figure,G).Thus, the
Figure.White Scales in Xeroderma Detectable by Dry Dermoscopy
Patient 1, clinical photographA Patient 1, dry dermoscopyB
Patient 2, clinical photographC Patient 2, dry dermoscopyD
Patient 1, hematoxylin-eosin stainH
Patient 3, dermoscopy without fluidE Patient 3, dermoscopy with 90%
ethanol
F
Patient 3, treated with an
emollient before dermoscopy
G
Xeroderma (XD) with features of beginning asteatotic eczema, Fitzpatrick skin
type II: A, Clinical view. B, Dermoscopy (original magnification ×10). XD,
Fitzpatrick skin type IV: C, Clinical view. D, Dermoscropy (original magnification
×10). E, Dermoscopy without fluid (original magnification ×10). F, Dermoscopy
with 90% ethanol. G, Dermoscopy with an emollient applied 15 minutes before.
H, Dermatopathology showing focal parakeratosis, spongiosis, lymphocytic
exocytosis, and scarce lymphohistocytic infiltrate in the upper dermis.
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WSS was useful in detecting xeroderma on native, untreated
skin.Thehistopathological featuresofabiopsyspecimentaken
in a spot of xerodermawith a positiveWSS showed parakera-
tosis and features of eczema (Figure, H).
Discussion | We have taken a positive WSS as a cue to discuss
andusually prescribe emollients.Manypatients arenot aware
that theyareaffectedbyxeroderma. Inourexperience, theWSS
revealed the condition in many cases; clinically, xeroderma
would have been missed because of the absence of wide-
spread and clinically obvious scaling. Xeroderma occurs not
only in old age4,5 but also among younger adults with eating
disorders,HIV infection, essential fatty aciddeficiency, atopic
dermatitis, andmany formsof ichthyosis. Scalingwithout xe-
roderma is usually temporary and can occur after inflamma-
tory rashes. As yet, few tono clinical criteria for detecting and
diagnosing xeroderma exist. We propose that clinicians look
for theWSS in patients of all ages. TheWSS can contribute to
thedetection anddiagnosis of xerodermaand thus allowsuit-
able treatment before asteatotic eczema develops.
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